Evidence map›Paper›PMID 42717239›Full record

ArticleNPJ digital medicine2026

PREDICT-GBM: A multicenter platform advancing personalized glioblastoma radiotherapy planning.

Lucas Zimmer, Jonas Weidner, Michal Balcerak, Florian Kofler, Mara Krupa, Ivan Ezhov, Santiago Cepeda, Ray Zirui Zhang, John S Lowengrub, Bjoern Menze and 1 more

Abstract read
In one paragraph

Article in NPJ digital medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Lucas ZimmerAI for Image-Guided Diagnosis and Therapy, Technical University of Munich, Munich, Germany. lucas.zimmer@tum.de.
Jonas WeidnerAI for Image-Guided Diagnosis and Therapy, Technical University of Munich, Munich, Germany.
Michal BalcerakDepartment of Quantitative Biomedicine, University of Zurich, Zurich, Switzerland.
Florian KoflerAI for Image-Guided Diagnosis and Therapy, Technical University of Munich, Munich, Germany.
Mara KrupaAI for Image-Guided Diagnosis and Therapy, Technical University of Munich, Munich, Germany.
Ivan EzhovAI in Healthcare and Medicine, Technical University of Munich, Munich, Germany.
Santiago CepedaDepartment of Neurosurgery, Río Hortega University Hospital, Valladolid, Spain.
Ray Zirui ZhangDepartment of Mathematical Sciences, Worcester Polytechnic Institute, Worcester, MA, USA.
John S LowengrubDepartment of Mathematics, University of California, Irvine, CA, USA.
Bjoern Menze *Department of Quantitative Biomedicine, University of Zurich, Zurich, Switzerland.
Benedikt Wiestler *AI for Image-Guided Diagnosis and Therapy, Technical University of Munich, Munich, Germany.

Funding

NVIDIA academic award Not applicable.
6 · The paper itself

Abstract

Glioblastoma recurrence is largely driven by diffuse infiltration beyond radiologically visible margins, yet current radiotherapy guidelines rely on uniform margin expansions that ignore patient-specific biology and anatomy. While computational models promise to map this invisible growth and guide personalized planning, their clinical translation is hindered by a lack of standardized benchmarking and reproducible validation. To bridge this gap, we present PREDICT-GBM, an open-source platform integrating a curated, longitudinal, multi-center dataset of 243 patients with a standardized evaluation pipeline. We benchmark a novel U-Net-based recurrence prediction model against state-of-the-art biophysical and data-driven methods. Under iso-volumetric constraints, both biophysical and deep-learning approaches achieved modest but statistically significant gains in geometric coverage of future recurrence over guideline-based plans. On the combined cohort, our U-Net achieved the highest mean coverage of enhancing recurrence (79.37 ± 2.08%), surpassing guideline-based plans (paired Wilcoxon signed-rank test, Benjamini-Hochberg adjusted p = 2.9 × 10

Identifiers

PMID42717239
PMCPMC13558737

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.